Table 4.
The effect of G-CSF on IL-6 release by monocytes derived from 10 healthy individuals. Enriched monocytes were incubated with various TLR agonists (for each individual two different concentrations were tested), and the IL-6 supernatant levels were compared for cultures with G-CSF and corresponding control cultures without G-CSF. The table presents the median and range of the IL-6 concentrations for all 20 cultures with each agonist (i.e., 10 healthy individuals tested with two concentrations of each agonist); control cultures of monocytes incubated in medium alone showed undetectable IL-6 levels. A significant difference was defined as at least a twofold increase/decrease in the presence of G-CSF—at least 20 pg/mL. Divergent effects between the two concentrations of an agonist were not observed for any agonist/donor combination. The dark color indicates a significant G-CSF induced IL-6 increase for at least one of the two agonist concentrations tested, whereas the bright color indicates a significant decrease. Cultures marked with nt means that these were tested with different LPS concentrations (0.1 and 0.5 ng/mL); none of these alternative LPS/donor combinations showed any significant influence of G-CSF on the IL-6 levels. Monocytes cultured in medium alone without G-CSF/TLR agonists showed undetectable IL-6 levels.
| Agonist | Agonist Concentration | IL-6 Supernatant Levels (pg/mL) | Healthy Monocyte Donors | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||
| PAM3CSK4 (TLR1/2) | 1 and 5 ng/mL | 10.8 (3.1–372) | ||||||||||
| LPS (TLR4) | 5 and 10 ng/mL | 3.1 (3.1–281) | nt | nt | nt | nt | nt | nt | nt | |||
| Flagelin (TLR5) | 10 and 50 ng/mL | 13.9 (3.1–291) | ||||||||||
| R848 (TLR7 > TLR8) | 50 and 100 ng/mL | 3.1 (3.1–180) | ||||||||||
| R837 (TLR7/TLR8) | 0.5 and 1 mg/mL | 188 (3.1–395) | ||||||||||